Sign in Subscribe
United States. Securities and Exchange Commission

Amgen Inc. Files SEC Form 8-K, Releasing 14 Documents on Material Corporate Changes

Strategic Insights

— 1 min read

Amgen Inc., a biopharmaceutical company, has made a significant filing with the U.S. Securities and Exchange Commission (SEC) on March 9, 2023, through Form 8-K, the "current report" used to disclose material events or corporate changes. This filing was made available to the public through the SEC's EDGAR database. As one of the leading biopharmaceutical companies, Amgen's filing is of importance to investors and security holders. The company's SIC code is 2836, Biological Products, and its headquarters is located at One Amgen Center Drive, Thousand Oaks, CA 91320.

Key Takeaways:

  • The filing was made by Amgen Inc. through Form 8-K, a document used to report material corporate changes.
  • The SEC filing, with file number 0001193125-23-066144, consists of 14 documents submitted to the commission.
  • Amgen's SIC code is 2836, Biological Products, and its company code is 318154.
  • The filing was made on March 9, 2023, and the contact information for the company is available on the SEC website.
  • The filing is part of the ongoing efforts by Amgen Inc. to maintain transparency and compliance with SEC regulations.
  • This filing is a formal document submitted by publicly-traded companies to disclose material corporate changes.
  • The documents submitted as part of this filing are available through the SEC's EDGAR database.

Statistics:

  • The filing consists of 14 documents submitted to the SEC.
  • The SIC code for Amgen Inc. is 2836, Biological Products.
  • The company's headquarters is located at One Amgen Center Drive, Thousand Oaks, CA 91320.
  • The SEC file number associated with this filing is 0001193125-23-066144.
  • The filing was made on March 9, 2023, and is available for public access through the SEC's EDGAR database.

Sources:

  • NewsRx, NewsReporter-Staff News Editor (2023, March 29). Amgen Inc. Files SEC Form 8-K, Releasing 14 Documents on Material Corporate Changes. Biotech Week.

Read more